BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv6.18.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20150329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20151025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20160327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20161030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20170326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20171029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160429
DTEND;VALUE=DATE:20160430
DTSTAMP:20160419T155753Z
CREATED:20160419T011244Z
LAST-MODIFIED:20160419T155753Z
UID:14882-1461888000-1461974399@ces.b2sg.org
SUMMARY:The search for the best cancer research in the world
DESCRIPTION:Since 1979 “worldwide cancer research” has invested into nearly two thousand reseach projects all over the world. The goal of this grant is to support research that might in future help reduce the incidence of cancer or improve cancer survial. \nGrants are awarded to support fudamental or translational research into the causes\, mechanisms\, diagnosis\, treatment or prevention of cancer. \nDuration of funding: 1-3years \nCovered costs: direct costs of conducting the research \nNationality: international
URL:https://ces.b2sg.org/event/the-search-for-the-best-cancer-research-in-the-world/
CATEGORIES:Grants
ATTACH;FMTTYPE=image/png:https://ces.b2sg.org/wp-content/uploads/2016/04/worldwide-cancer-research1.png
END:VEVENT
END:VCALENDAR